Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Research Abstract |
A clinical study of WT1-peptide-based cancer vaccine(WT1 vaccine) in combination with gemcitabine was performed for the patients with advanced pancreatic cancer. I focused on the association between clinical efficiency and WT1-specific immunological monitoring, such as i) delayed-type hypersensitivity(DTH) to WT1 peptide and ii) WT1-specific cytotoxic lymphocytes in the peripheral blood(WT1-CTLs). An association between longer survival and DTH-positivity was statistically significant, and longer survivors had higher frequency of WT1-CTLs with memory phenotype.
|